Accenture invests in Iridius for compliant AI in life sciences

Accenture (NYSE: ACN) has invested through Accenture Ventures in Iridius, an enterprise AI infrastructure company that develops compliant AI solutions for regulated industries including life sciences and pharmaceuticals, according to a press release statement.

The companies will form a strategic partnership to help life sciences organizations scale AI adoption while ensuring compliance, traceability, and auditability are integrated throughout implementation processes.

The collaboration aims to combine Accenture's industry knowledge with Iridius' AI-powered regulatory and compliance capabilities to enable enterprise-wide AI transformation beyond isolated pilot programs. The partnership will focus on building compliance workflows across the life sciences value chain, including regulatory submissions, pharmacovigilance, clinical operations, and manufacturing.

Iridius' platform transforms regulations and standard operating procedures into machine-readable logic, embedding compliance directly into enterprise workflows. The technology includes a knowledge engine that translates regulatory standards into structured logic and an intelligent solution factory for orchestrating compliant workflows across pharmaceutical operations.

"Our investment in Iridius is about giving life sciences organizations the ability to innovate without hesitation," said Ray Pressburger, global life sciences lead at Accenture. "By embedding compliance into the core of AI, we're helping accelerate clinical development, improve decision-making, and bring therapies to patients faster, all while meeting the rigorous expectations of regulators worldwide."

Mike Kropp, Co-Founder and CEO of Iridius, stated the partnership helps customers "reimagine complex workflows with AI, turning it from a risk to manage into a trusted capability that strengthens compliance, enables innovation with confidence, and makes compliance a strategic advantage."

Investment terms were not disclosed. The collaboration addresses increasing pressure on life sciences organizations to accelerate development timelines while maintaining regulatory compliance and patient safety standards.

You May Also Be Interested In

• Accenture plc (ACN) PT Lowered to $150 at Truist Securities
• Accenture (ACN) spreader of 22700 contracts of August 120 puts and 22200 contracts of August 130 calls as share price down 7.2%
• Organon launches two denosumab biosimilars in Canada